49,855 Shares in Royalty Pharma PLC $RPRX Bought by Partners Group Holding AG

Partners Group Holding AG purchased a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 49,855 shares of the biopharmaceutical company’s stock, valued at approximately $1,926,000.

A number of other large investors have also recently bought and sold shares of the business. Cullen Frost Bankers Inc. boosted its stake in Royalty Pharma by 19.5% during the 4th quarter. Cullen Frost Bankers Inc. now owns 546,350 shares of the biopharmaceutical company’s stock worth $21,111,000 after purchasing an additional 89,253 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in Royalty Pharma during the 4th quarter worth $4,923,000. Tredje AP fonden lifted its stake in shares of Royalty Pharma by 44.8% in the 4th quarter. Tredje AP fonden now owns 53,464 shares of the biopharmaceutical company’s stock worth $2,066,000 after acquiring an additional 16,545 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of Royalty Pharma by 21.6% in the 4th quarter. Handelsbanken Fonder AB now owns 315,686 shares of the biopharmaceutical company’s stock worth $12,198,000 after acquiring an additional 56,061 shares during the period. Finally, Resona Asset Management Co. Ltd. lifted its stake in shares of Royalty Pharma by 0.4% in the 4th quarter. Resona Asset Management Co. Ltd. now owns 114,910 shares of the biopharmaceutical company’s stock worth $4,440,000 after acquiring an additional 474 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Shares of RPRX opened at $52.41 on Wednesday. The company has a 50-day simple moving average of $48.58 and a 200-day simple moving average of $43.61. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. The company has a market capitalization of $30.18 billion, a PE ratio of 35.65, a P/E/G ratio of 1.43 and a beta of 0.40. Royalty Pharma PLC has a 52-week low of $32.15 and a 52-week high of $53.47.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $631.00 million during the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. Equities research analysts predict that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.

Insider Activity

In other news, Director Gregory Norden sold 3,045 shares of the stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the transaction, the director owned 191,803 shares in the company, valued at $10,165,559. This trade represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.06, for a total transaction of $726,073.04. Following the completion of the transaction, the executive vice president owned 31,881 shares of the company’s stock, valued at $1,691,605.86. This represents a 30.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 155,893 shares of company stock worth $7,512,360 in the last 90 days. 18.84% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on RPRX. JPMorgan Chase & Co. raised their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Morgan Stanley raised their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Finally, Citigroup raised their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $53.71.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.